Publikationen in Zusammenarbeit mit Forschern von Orlando Immunology Center (7)

2020

  1. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

    The Lancet HIV, Vol. 7, Núm. 1, pp. e16-e26

2019

  1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

    The Lancet HIV, Vol. 5, Núm. 5, pp. e211-e220

  2. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

    The Lancet HIV, Vol. 5, Núm. 4, pp. e162-e171

2016

  1. The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial

    Medicine (United States), Vol. 95, Núm. 6

2006

  1. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations

    HIV Clinical Trials, Vol. 7, Núm. 2, pp. 86-96

  2. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

    Lancet, Vol. 368, Núm. 9534, pp. 476-482